
"FDA Approves New COVID Prophylactic for Immunocompromised Individuals"
The FDA has authorized Pemgarda, a new monoclonal antibody infusion, for emergency use in immunocompromised individuals aged 12 and older who are unlikely to mount an adequate immune response after vaccination. This includes those who have received organ transplants or are undergoing cancer treatment. Pemgarda will be available in the next week or two and is administered as an infusion in healthcare settings. The drug aims to protect a small but vital group of individuals who are most at risk from Covid-19.
